huRHO-P347S小鼠

复苏/繁育服务
产品名称

huRHO-P347S

产品编号

C002130

品系全称

C57BL/6Cya-Rhotm5(hRHO*P347S)/Cya

品系背景

C57BL/6Cya

品系状态

使用本品系发表的文献需注明: huRHO-P347S mice (Catalog C002130) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
小计:
询价

基本信息

应用领域

基因
RHO
基因别称
RP4,OPN2,CSNBAD1
染色体号
Chr 3 (Human)
MGI ID

品系介绍

视网膜色素变性(Retinitis Pigmentosa, RP)是一种遗传性视网膜疾病,全球患病率约为1:5000-1:3000。RP具有很大的临床和遗传异质性,视紫红质基因(Rhodopsin, RHO)突变导致约25%的显性RP [1]。RHO编码的视紫红蛋白与视觉光传导和GPCR下游信号密切相关,视紫红蛋白在视觉形成过程中光信号的传导至关重要,大多数RHO突变导致视紫红蛋白在感光细胞中高水平表达,使得大量的突变蛋白在细胞中定位异常并聚集,造成感光细胞凋亡,不能行使正常的光信号传导功能。此外,RHO基因的突变也与先天性静止性夜盲(CSNB)有关 [2-6]。P347S(Pro347Ser)突变位于视紫红质(RHO)蛋白的C末端胞质尾部,可能影响视紫红质向视杆细胞外节的定向运输与定位,导致部分突变蛋白异常分布,并伴随细胞外囊泡积累,最终引发光感受器细胞进行性退变。P347S是已报道的常染色体显性遗传性视网膜色素变性(adRP)相关致病突变之一 [7-9]。
huRHO-P347S小鼠是通过基因编辑技术将小鼠Rho基因起始密码子至5号外显子下游的序列替换为人源RHO基因起始密码子至5号外显子下游的序列,并将点突变p.P347S(CCG to TCG)引入至人源RHO基因的5号外显子中。该模型可用于研究RHO基因突变相关的常染色体显性遗传性视网膜色素变性(adRP)的发病机制、疾病进展及潜在治疗策略的临床前评价。此外,基于自主研发的TurboKnockout融合BAC重组的技术创新,赛业生物还可基于huRHO全基因组人源化小鼠针对不同点突变提供定制服务,以满足广大研发人员关于视网膜色素变性(RP)疾病的药效学等实验需求。
参考文献
Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809.
Meng D, Ragi SD, Tsang SH. Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Mol Ther. 2020 Oct 7;28(10):2139-2149.
Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem. 2011 Mar 25;286(12):10551-67.
Dryja T P, Mcgee T L, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitispigmentosa[J]. Nature, 1990, 343(6256):364-366.
Zhang X, Fu W, Pang C P, et al. Screening for point mutations in rhodopsin gene among one hundred Chinese patients with retinitis pigmentosa[J]. Chinese Journal of Medical Genetics, 2002, 19(6):463-466.
Gamundi M J, Hernan I, Muntanyola M, et al. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa[J]. Human Mutation, 2008.
Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proceedings of the National Academy of Sciences. 1996;93(24):14176–14181.
Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, Cheetham ME. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018 Jan;62:1-23.
Bonilha VL, Rayborn ME, Bell BA, Marino MJ, Beight CD, Pauer GJ, Traboulsi EI, Hollyfield JG, Hagstrom SA. Retinal histopathology in eyes from patients with autosomal dominant retinitis pigmentosa caused by rhodopsin mutations. Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2161-9.

构建方案

将小鼠Rho基因起始密码子至5号外显子下游的序列替换为人源RHO基因起始密码子至5号外显子下游的序列,并将点突变p.P347S(CCG to TCG)引入至人源RHO基因的5号外显子中。
图1. huRHO-P347S小鼠的基因编辑策略示意图。
图1. huRHO-P347S小鼠的基因编辑策略示意图。